Crispr Therapeutics failed to meet market expectations in its latest earnings report, missing the projected result by $0.11 per share. Revenue also came in below estimates.
The available report does not provide the company’s reported earnings figure, revenue total, analyst consensus or additional details about the factors behind the shortfall.
Sources: Investing.com News.